Accuray Incorporated (NASDAQ:ARAY) shares rose 7.4% on Wednesday after an insider bought additional shares in the company. The company traded as high as $5.30 and last traded at $5.24. Approximately 2,373,202 shares were traded during trading, an increase of 219% from the average daily volume of 744,697 shares. The stock had previously closed at $4.88.
Specifically, CEO Joshua Levine bought 25,000 shares of the business’s stock in a transaction dated Monday, November 5th. The shares were purchased at an average cost of $4.75 per share, with a total value of $118,750.00. Following the completion of the purchase, the chief executive officer now owns 1,356,036 shares in the company, valued at approximately $6,441,171. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Shigeyuki Hamamatsu sold 8,762 shares of the stock in a transaction on Tuesday, October 2nd. The stock was sold at an average price of $4.48, for a total value of $39,253.76. Following the completion of the sale, the chief financial officer now directly owns 116,238 shares in the company, valued at $520,746.24. The disclosure for this sale can be found here. Over the last three months, insiders sold 48,378 shares of company stock worth $218,502. Insiders own 3.40% of the company’s stock.
ARAY has been the topic of a number of recent research reports. Jefferies Financial Group reissued a “buy” rating and issued a $6.00 target price on shares of Accuray in a research note on Friday, August 17th. BidaskClub cut Accuray from a “sell” rating to a “strong sell” rating in a research report on Friday, August 17th. Citigroup raised Accuray from a “sell” rating to a “neutral” rating and increased their price objective for the company from $3.50 to $3.90 in a research report on Thursday, November 1st. Finally, BTIG Research reaffirmed a “hold” rating on shares of Accuray in a research report on Wednesday, August 22nd. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $6.36.
The company has a debt-to-equity ratio of 2.70, a current ratio of 1.68 and a quick ratio of 1.04. The stock has a market cap of $410.86 million, a P/E ratio of -18.71 and a beta of 1.60.
Accuray (NASDAQ:ARAY) last released its quarterly earnings data on Tuesday, October 30th. The medical equipment provider reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.02). Accuray had a negative net margin of 5.79% and a negative return on equity of 42.15%. The business had revenue of $95.83 million for the quarter, compared to analysts’ expectations of $95.10 million. During the same period last year, the business earned ($0.11) earnings per share. On average, analysts predict that Accuray Incorporated will post -0.14 EPS for the current fiscal year.
Several institutional investors have recently added to or reduced their stakes in ARAY. BlackRock Inc. boosted its position in shares of Accuray by 10.0% during the first quarter. BlackRock Inc. now owns 8,090,671 shares of the medical equipment provider’s stock valued at $40,454,000 after buying an additional 737,107 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Accuray by 41.9% in the first quarter. Dimensional Fund Advisors LP now owns 1,874,105 shares of the medical equipment provider’s stock worth $9,371,000 after purchasing an additional 553,814 shares during the last quarter. Assenagon Asset Management S.A. purchased a new position in Accuray in the third quarter worth about $1,668,000. JPMorgan Chase & Co. boosted its position in Accuray by 1,329.4% in the third quarter. JPMorgan Chase & Co. now owns 324,279 shares of the medical equipment provider’s stock worth $1,459,000 after purchasing an additional 301,593 shares during the last quarter. Finally, Systematic Financial Management LP purchased a new position in Accuray in the second quarter worth about $1,064,000. 83.56% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “Accuray (ARAY) Stock Price Up 7.4% Following Insider Buying Activity” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another publication, it was stolen and republished in violation of United States & international copyright and trademark laws. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/11/07/accuray-aray-stock-price-up-7-4-following-insider-buying-activity.html.
About Accuray (NASDAQ:ARAY)
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body.
Read More: What Is An Exchange-Traded Fund (ETF)?
Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.